Pandect Bioventures

Pandect Bioventures functions as a venture capital firm, dedicating resources to early-stage biotech and pharmaceutical companies from seed to Series A and beyond. The firm's core offering extends beyond capital, encompassing comprehensive management support designed to guide entrepreneurs through crucial business milestones. This involves a strategic approach to identifying transformative healthcare concepts early on, bolstered by access to an extensive ecosystem including a 40,000-square-foot incubator, specialized expertise from academic and industry advisors, and collaborative partnerships with leading research institutions.

The firm was founded in 2018 by Managing Directors Walter H. Moos, PhD, Mohamad Tabrizi, MBA, and Michael X. Hui, MBA. A foundational insight driving the firm's establishment, articulated by Dr. Moos, stems from recognizing the prevalent challenges faced by promising therapeutic innovations within the drug discovery and development cycle, often referred to as the "valley of death." This understanding spurred the creation of a supportive environment aimed at nurturing these advancements.

Pandect Bioventures serves scientific innovators and entrepreneurs within the biotech and pharma sectors, aiming to accelerate the progression of their discoveries to patients. The company's long-term vision is centered on mitigating the risk of promising therapeutic innovations failing due to lack of early-stage support. By adopting a founder-centric model, Pandect Bioventures works to advance scientific breakthroughs through critical value-inflection points and ensure their successful development.